2008
High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer
Ghosh S, Sullivan CA, Zerkowski MP, Molinaro AM, Rimm DL, Camp RL, Chung GG. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathology 2008, 39: 1835-1843. PMID: 18715621, PMCID: PMC2632946, DOI: 10.1016/j.humpath.2008.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularConnecticutFemaleFluorescent Antibody Technique, IndirectHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesKaplan-Meier EstimateMiddle AgedNeuropilin-1Receptors, Vascular Endothelial Growth FactorSurvival RateTissue Array AnalysisVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2Young AdultConceptsVascular endothelial growth factorEndothelial growth factorBreast cancerVEGFR-1Growth factorNeuropilin-1VEGFR-2Kaplan-Meier survival analysisBreast cancer tissue microarrayVascular endothelial growth factor receptorPrimary breast cancerStandard prognostic factorsEndothelial growth factor receptorPrimary breast adenocarcinomaCancer tissue microarrayTumor-specific expressionGrowth factor receptorPrognostic factorsPrognostic significancePrognostic valueWorse outcomesLarge cohortTissue microarraySurvival analysisSignificant associationNuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions
Rothberg BE, Moeder CB, Kluger H, Halaban R, Elder DE, Murphy GF, Lazar A, Prieto V, Duncan LM, Rimm DL. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Modern Pathology 2008, 21: 1121-1129. PMID: 18552823, PMCID: PMC2570478, DOI: 10.1038/modpathol.2008.100.Peer-Reviewed Original ResearchAntigens, NeoplasmBiomarkers, TumorCell NucleusDiagnosis, DifferentialFluorescent Antibody Technique, IndirectGp100 Melanoma AntigenHumansImage Processing, Computer-AssistedImmunoenzyme TechniquesMelanomaMelanoma-Specific AntigensMembrane GlycoproteinsNeoplasm ProteinsNevus, PigmentedSkin NeoplasmsTissue Array Analysis
2004
Novel tyramide‐based tyrosinase assay for the detection of melanoma cells in cytological preparations
Angeletti C, Khomitch V, Halaban R, Rimm DL. Novel tyramide‐based tyrosinase assay for the detection of melanoma cells in cytological preparations. Diagnostic Cytopathology 2004, 31: 33-37. PMID: 15236262, DOI: 10.1002/dc.20051.Peer-Reviewed Original ResearchMeSH KeywordsBiopsy, Fine-NeedleCell Line, TumorFemaleFluorescent Antibody Technique, IndirectHumansImage Processing, Computer-AssistedMelanomaMicroscopy, FluorescenceMiddle AgedMonophenol Monooxygenase
2002
Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray
Chung GG, Kielhorn EP, Rimm DL. Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray. Clinical Colorectal Cancer 2002, 1: 237-242. PMID: 12450422, DOI: 10.3816/ccc.2002.n.005.Peer-Reviewed Original ResearchMeSH KeywordsAvidinBeta CateninBiomarkers, TumorChi-Square DistributionColorectal NeoplasmsCytoskeletal ProteinsFluorescent Antibody Technique, IndirectHistocytological Preparation TechniquesHorseradish PeroxidaseHumansImmunohistochemistryTrans-ActivatorsTyramineConceptsTissue microarrayTissue sectionsColorectal cancer tissue microarraySemiquantitative grading systemColorectal cancer specimensCancer tissue microarrayPatient outcomesLarge cohortSubjective assessmentCancer specimensImmunohistochemical methodsGrading systemNuclear stainingPathology literatureProtein expressionTissue samplesCell preparationsExpression levelsBeta-catenin antibodyCurrent standardImmunohistochemistryCohortOutcomesApparent increaseExpression
1999
Frequent Nuclear/Cytoplasmic Localization of β-Catenin without Exon 3 Mutations in Malignant Melanoma
Rimm D, Caca K, Hu G, Harrison F, Fearon E. Frequent Nuclear/Cytoplasmic Localization of β-Catenin without Exon 3 Mutations in Malignant Melanoma. American Journal Of Pathology 1999, 154: 325-329. PMID: 10027390, PMCID: PMC1850000, DOI: 10.1016/s0002-9440(10)65278-9.Peer-Reviewed Original ResearchMeSH KeywordsBeta CateninCell NucleusCytoplasmCytoskeletal ProteinsDNA PrimersDNA, NeoplasmExonsFluorescent Antibody Technique, IndirectHumansMelanomaMutationSignal TransductionSkin NeoplasmsTrans-ActivatorsConceptsCytoplasmic localizationPhosphorylation sitesE-cadherin-mediated cell-cell adhesionGlycogen synthase kinase 3beta phosphorylation sitesMelanoma cell linesN-terminal phosphorylation sitesWnt pathwayExon 3 mutationsCell linesGlycogen synthase kinase-3betaFactor transcription factorsBeta-catenin accumulatesCell-cell adhesionSynthase kinase-3betaBeta-catenin exon 3 mutationsDNA sequencing studiesAdenomatous polyposis coliAxin proteinTranscription factorsKinase-3betaAmino terminusBeta-CateninBeta-catenin mutationsWnt pathway activationSequencing studies
1998
Expression of c‐met is a strong independent prognostic factor in breast carcinoma
Ghoussoub R, Dillon D, D'Aquila T, Rimm E, Fearon E, Rimm D. Expression of c‐met is a strong independent prognostic factor in breast carcinoma. Cancer 1998, 82: 1513-1520. PMID: 9554529, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1513::aid-cncr13>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsBreast carcinomaIndependent predictorsStrong independent prognostic factorCox proportional hazards modelGrowth factorIndependent prognostic factorLymph node statusSubset of patientsInvasive ductal carcinomaUseful prognostic markerProportional hazards modelBreast tumor specimensHepatocyte growth factorNegative patientsPrognostic factorsAggressive diseaseDuctal carcinomaNode statusPrognostic valuePrognostic markerTumor specimensHazards modelPatientsPredictive valueSurvival rate